Spyros Mezitis, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1013078732
Payments from drug & device makers
Across 392 payments — averaging $52.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Boehringer Ingelheim$2K
- Novo Nordisk$782
- Pfizer$583
- Lilly USA, LLC$557
- Corcept Therapeutics$543
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$11,37556%
- Food & beverage$8,99344%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $13,401 |
| Boehringer Ingelheim | 64 | $1,568 |
| Novo Nordisk | 37 | $782 |
| Pfizer | 27 | $583 |
| Lilly USA, LLC | 26 | $557 |
| Corcept Therapeutics | 17 | $543 |
| AstraZeneca(2 entities) | 27 | $530 |
| Sanofi-aventis U.S. LLC | 20 | $448 |
| Aytu Biopharma, Inc. | 4 | $260 |
| Mannkind Corporation | 2 | $249 |
| Merck | 13 | $235 |
| IBSA Pharma Inc. | 7 | $149 |
| Amgen(2 entities) | 7 | $143 |
| Intra-sana Laboratories | 5 | $132 |
| Xeris Pharmaceuticals, Inc. | 5 | $106 |
| Abbott | 4 | $94 |
| Astellas Pharma US Inc | 4 | $76 |
| Ultragenyx Pharmaceutical Inc. | 4 | $70 |
| Bayer | 3 | $67 |
| Antares Pharma, Inc. | 2 | $54 |
| Kyowa Kirin, Inc. | 2 | $50 |
| Exact Sciences | 2 | $40 |
| Recordati_rare_diseases_inc. | 2 | $38 |
| Medtronic | 1 | $32 |
| Acerus Pharmaceuticals Corporation | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Chiesi USA, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Avion Pharmaceuticals | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,388 in reported general payments places this provider in the 80th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 43 | $47,596 |
| JanuviaSitagliptin Phosphate | 43 | $47,572 |
| OzempicSemaglutide | 42 | $44,605 |
| TradjentaLinagliptin | 33 | $33,397 |
| JardianceEmpagliflozin | 36 | $33,206 |
| EliquisApixaban | 27 | $32,556 |
| SynthroidLevothyroxine Sodium | 290 | $27,569 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $17,411 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $14,835 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $12,497 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,004 |
| VascepaIcosapent Ethyl | 11 | $6,059 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $5,047 |
| HumalogInsulin Lispro | 15 | $3,399 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $1,568 | $66,60269 claims |
| MerckJanuvia, Janumet | $235 | $62,40761 claims |
| Lilly USA, LLCMounjaro, Humalog | $557 | $50,99558 claims |
| Novo NordiskOzempic | $782 | $44,60542 claims |
| PfizerEliquis | $583 | $32,55627 claims |
| AbbVieSynthroid | $13,401 | $27,569290 claims |
| AstraZenecaBreztri Aerosphere | $530 | $7,00411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $40730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.